Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLoans - Loss AllowanceNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

RedHill Biopharma (RDHL) Loans - Loss Allowance: 2012-2025

Historic Loans - Loss Allowance for RedHill Biopharma (RDHL) over the last 6 years, with Jun 2025 value amounting to $22.7 million.

  • RedHill Biopharma's Loans - Loss Allowance rose 2966.94% to $22.7 million in Q2 2025 from the same period last year, while for Jun 2025 it was $22.7 million, marking a year-over-year increase of 2966.94%. This contributed to the annual value of -$414.8 million for FY2024, which is 201.73% down from last year.
  • According to the latest figures from Q2 2025, RedHill Biopharma's Loans - Loss Allowance is $22.7 million, which was up 105.48% from -$414.8 million recorded in Q4 2024.
  • Over the past 5 years, RedHill Biopharma's Loans - Loss Allowance peaked at $433.9 million during Q4 2022, and registered a low of -$414.8 million during Q4 2024.
  • For the 3-year period, RedHill Biopharma's Loans - Loss Allowance averaged around $3.8 million, with its median value being $2.6 million (2023).
  • As far as peak fluctuations go, RedHill Biopharma's Loans - Loss Allowance slumped by 201.73% in 2024, and later spiked by 2,966.94% in 2025.
  • Over the past 5 years, RedHill Biopharma's Loans - Loss Allowance (Quarterly) stood at $22.7 million in 2021, then soared by 35.43% to $433.9 million in 2022, then dropped by 6.02% to $407.7 million in 2023, then slumped by 201.73% to -$414.8 million in 2024, then surged by 2,966.94% to $22.7 million in 2025.
  • Its Loans - Loss Allowance stands at $22.7 million for Q2 2025, versus -$414.8 million for Q4 2024 and $741,000 for Q2 2024.